Pathology of sentinel lymph nodes for melanoma

M G Cook, S Di Palma

ABSTRACT

As a concept sentinel lymph node biopsy seems attractive in that it attempts to identify the first lymph node, rather than the nearest node, draining a particular anatomic area where a tumour has arisen. Pathological assessment can then indicate whether metastases are present and the procedure is either a strong prognostic indicator or possibly therapeutic in itself. These comments apply to any tumour type, but with melanoma the pathological procedure is more problematic and any benefits above prognosis and staging are not universally accepted. The procedure does give accurate staging without the extra morbidity of regional node dissection and many patients gain psychological support from the information gained.

POTENTIAL BENEFITS OF SENTINEL LYMPH NODE BIOPSY FOR MELANOMA

Excision of the sentinel lymph node (SLN) enables a prognostic assessment to be made that is more powerful than thickness measurements on the primary. This is itself sufficient, to many, to justify the procedure since it has low morbidity. The SLN status is an important criterion for entry into clinical trials and therefore until a clear effective systemic therapy is established SLN into clinical trials and therefore until a clear effective systemic therapy is established SLN biopsy (SLNB) will have importance and the SLN status may be the threshold to entry into a treatment programme.

The initial reason for development of SLNB was to enable selection of patients more likely to receive benefits from regional node dissection (RND). It had already been shown that RND was not effective on unselected patients but in the absence of alternatives the surgical treatment option was retained. The SLNB seemed a way of directing RND to a group of patients more likely to benefit from wide excision of nodes. This remains the usual procedure, although evolution towards offering RND to an even more restricted group of patients is proceeding. Whether SLNB by itself is of therapeutic benefit is not yet established. There is a suggestion of prolongation of disease-free survival for SLNB patients as compared with observation followed by RND only when clinical evidence of metastases develops. Prolongation of overall survival has not yet been demonstrated but longer follow-up may reveal this.

POTENTIAL PROBLEMS OF SLNB

Any disadvantages of SLNB are also not established. The anxieties about an increase in “in transit” metastases have not been upheld. The theoretical concern about removal of what is likely to be the first line of immunological defence still requires further study. A suggested alternative procedure is high-grade ultrasound, but 4.5 mm is the smallest size that can be consistently detected with this technique and the majority of metastases in SLN for melanoma are smaller than that and therefore this alternative does not appear acceptable as a substitute for SLNB. The SLNB procedure has some associated morbidity but this is much less than for RND, and at least 70% of patients with melanoma will avoid this morbidity by having the lesser procedure. The National Institute for Health and Clinical Excellence (NICE) report on skin tumours9 has concluded that SLNB has merit for staging, and that it should continue to be done in existing centres as part of clinical trials, but has not wholeheartedly recommended SLNB for all melanoma. This recommendation is in spite of the current paucity of suitable trials into which to enter patients. The NICE advice may need modification in the light of the recent report of MSLT-1 since some prolongation of disease-free survival has been demonstrated2 and improved overall survival cannot be ruled out.

SURGICAL PROCEDURES EFFECTING PATHOLOGICAL ASSESSMENT

The identification of the SLN by the surgeon should be based on preoperative lymphoscintigraphy and intraoperative injection of vital blue dye and radiocolloids. The lymphoscintigraphy demonstrates the direction of the lymph drainage from any cutaneous site and enables the first or sentinel lymph nodes in each basin to be identified and marked on the overlying skin. There is some variation in definitions of SLN and so there may be variation in the numbers of SLN excised between surgeons or between centres.

The SLN should be excised with a cuff of fat and without trauma to the node. Examination of the subcapsular zone of the SLN is most likely to reveal metastases and so it is important that this should not be damaged by the surgery. Confirmation of what is a true SLN may be obtained by using carbon dye injected at the primary site. This tends to be localised in the area most likely to contain metastases and its presence confirms the node as a true SLN. Unfortunately this carbon preparation is not available in all countries. Where the surgeon sees the afferent lymphatics with the blue dye he can use a ligature to identify this aspect of the node so that the pathologist is aware of the orientation of the node, and this therefore facilitates the slicing through the median plane.

HISTOPATHOLOGICAL AND PATHOBIOLOGICAL PECULIARITIES OF MELANOCYTIC TUMOURS AFFECTING INTERPRETATION OF SLN

In contrast to interpretation of SLN for other malignancies, melanoma presents extra difficulties due to its tendency to metastasise in small groups
or even single cells, which on conventional H&E staining are similar to other cells normally present in lymph nodes at least at scanning magnification. The assessment of the lymph node must be designed to detect as many as possible of these metastases. To detect all of them would involve serial sectioning of the SLN to extinction resulting in thousands of sections per node. This is clearly not practicable and a balance between workload and efficiency is required and several procedures have been developed.

PATHOLOGICAL PROCEDURES

Dissection

Dissection of the SLN can be by random parallel “bread loaf” slicing or single slicing through the central plane (bivalve technique).

Since Cochrane, in an early study, showed that the majority of metastases are in a central plane (see fig 1), the bivalve technique, in which a slice is made through the convex capsule and the hilum to reveal the maximum cut surface area, has been adopted by us. The alternative technique recommended by Starz et al consists of slicing the SLN at 2 mm intervals. It is attractive in that it does not depend on the slightly difficult identification of a central plane and also in that it does not require multiple sections on each slice. However, in larger nodes, there may be a need for several blocks.

On balance we have preferred to use the bivalving approach, but using some dissection of the lymph node from the surrounding fat followed by a combined visual assessment and palpation to identify the central plane through which the node is bisected.

Sectioning and staining

Further options exist in the sectioning and staining of the bivalved node. Cochran recommended serial sections from the two mid-plane surfaces stained with a combination of H&E and melanocyte markers (S100, HMB45, Melan A). Starz examined two mid-plane surfaces stained with a combination of H&E and Starz et al 11 consists of slicing the SLN at 2 mm intervals. It is attractive in that it does not depend on the slightly difficult identification of a central plane and also in that it does not require multiple sections on each slice. However, in larger nodes, there may be a need for several blocks.

On balance we have preferred to use the bivalving approach, but using some dissection of the lymph node from the surrounding fat followed by a combined visual assessment and palpation to identify the central plane through which the node is bisected.

Figure 1  Metastases of melanoma are said to occur close to the median plane of the sentinel lymph node and therefore bivalving, as shown, and embedding face down in the cassette are recommended.

The particular antibody used depends on local preference. We have tried HMB45, MelanA, MiTF and S100. Melan A and HMB45 are widely used but they can be criticised as being less sensitive; however, on the other hand they have the advantage of being more specific. S100 has been chosen as the first-line antibody since it is the most sensitive, the least demanding technically, and the cheapest. However, it does require the pathologist to gain experience in its interpretation, particularly in distinguishing melanocytes from clumps of dendritic cells. We have overcome this rare problem by always having unstained adjacent sections for more specific antibodies in reserve for use in more problematic cases. We use Melan A most often for this confirmatory purpose. We have found HMB45 positivity in only 70% of melanomas and therefore do not regard it as sufficiently sensitive. A cocktail of antibodies including Melan A, HMB45, S100 and tyrosinase such as Pan Mel+ (Biocare Medical, Concord, California, USA) has high sensitivity and specificity but is more expensive and technically more demanding. With experience, S100 has the highest sensitivity and particularly in combination with diamobenzidine chromogen even single cells can be identified on screening magnification and confirmed on the adjacent H&E. This enables distinction from other potentially positive cells such as dendritic cells and nerves. We assess the same cells on immediately adjacent sections stained with H&E. Unless we are convinced that the immunohistochemistry positivity corresponds with a cell with cytological features of a melanocyte, we do not regard the SLN as positive.

Melanophages may sometimes be identified without melanocytes in the SLN and it could be speculated that these features represent intranodal regression, but the melanophages could equally well represent drainage of melanophages from the primary melanoma. These are particularly numerous when the primary melanoma shows features of regression.

Balancing extended sectioning against reverse transcription-PCR

In the early stages of development of SLN pathology protocols, the possibility of using molecular techniques such as reverse transcription (RT)-PCR on fresh tissue instead of histology was considered. Positivity in SLN for melanoma using tyrosinase and or MART-1 or gp100 was found to be much higher than that obtained using histology, even up to 72% positive. This high positivity far exceeded what would be expected from our knowledge of the natural history of melanoma unless the selection of cases was highly selected in favour of extremely poor prognosis patients. However the comparison between histology and molecular techniques was not adequately controlled, most obviously in that the lymph nodes were divided in an unspecified way and the separate parts assessed by only one of the two techniques. This took no account of the distribution of the metastases in the nodes.

We decided that the role of molecular biology needed to be evaluated in a more controlled manner, and we found that a positivity of 45% with RT-PCR on frozen sections did exceed what was obtained from immediately adjacent sections stained conventionally (15% positive), but that the discrepancy could be explained partly by the presence of naevus cells, which would also give a positive RT-PCR result, and partly by the presence of further melanoma deeper in the node only detected by more sections.

We achieved a detection rate of 33.8% by extending the sectioning protocol to six pairs of sections at 50 μm intervals. Each pair was stained with H&E and S100. Other unstained spare sections were taken at each 50 μm step. Further levels
deeper than the sixth pair produced only a minimal improve-
ment in detection rate and therefore the six pairs at 50 μm
intervals protocol was adopted by us as a reasonable balance
between workload and sensitivity.14

The detection rate of 33.8% was still below 45% detected by
RT-PCR but this is explained almost entirely by the presence of
naeuc cells. Others17 have suggested that this protocol is too
labour intensive or expensive. More importantly the significa-
tion of the additional metastases needs to be established.

We do not regard the extra work as excessive since in more
than 70% of SLN that are negative only seven slides need to be
examined per lymph node. This is achieved by using S100 as a
preliminary stain for scanning and one H&E to rule out other
pathology. In the 30% of cases that are positive, more detailed
assessment is required. Occasional melanomas are S100 negative
(1% in our experience), but metastases are still identified easily
as a negative or clear area against the blue counterstained
background.

The only variation in the sectioning protocol occurs when
lymph nodes are unusually rounded rather than approximately
reniform. In those thicker lymph nodes we use a wider step
between the pairs of stained sections, increasing it from 50 μm
to 75 or 100 μm.

It may be that the protocol we have adopted14 in the long
term may be shown to be excessively rigorous since Van Akkooi
et al18 have shown that metastases <0.1 mm are not associated
with further disease. However we consider that all metastases
however small have yet to be shown not to be capable of
progressing to more aggressive disease even after many years.
We have some experience of metastases remaining small and
localised in lymph nodes for several years after excision of the
primary melanoma. This is presumably the explanation of how
some melanoma metastases occasionally progress 10 or more
years after excision of the primary. It remains to be shown
whether some melanoma metastases are not capable of
progression by reason of different biology related to their
genetic profile, and therefore at least until that is proved and
such cases are identifiable, detection of as many as possible
of metastases should be the aim. This is supported by finding that
so-called isolated tumour cells in groups less than 0.2 mm are
associated with a lower overall survival.27

At least for the foreseeable future we recommend the protocol
as outlined in table 1 using S100 as a screening stain so that the
procedure is not too time consuming. RT-PCR is not ideal at
least for detection of metastases but work of Hoon et al19 and
Chew et al (unpublished) indicate that it may be useful in
providing additional prognostic information.

Naevus cells in SLN

One of the main difficulties in interpretation of SLN is the
presence of benign naevus cells. These are detected by S100 but
are almost always negative with HMB45, so that marker can be
used to distinguish naevus cells from metastatic melanoma.19
However, not all melanomas are positive with HMB45 (70% in
our experience), so that negativity is not a confirmation of
benign nature.

More importantly, naeuc cells can be distinguished from
metastases by their site and cytology. We have assessed the SLN
from 2005 patients with cutaneous melanoma, and 14% of
them contained naeuc cells mostly in the substance of the
fibrous capsule but occasionally in the fibrous trabecule. The
cells are usually characteristically naevoid with small dense
deci or little cytoplasm. However, very occasionally, collec-
tions of naeucoid cells are quite large so that they appear to
encroach into the adjacent lymph node. In those cases, while
necle are still highly unifrom, nucleoli can become evident.
In these rare difficult cases we use HMB45 (as recommended by
Murray et al19) and MIB1. The HMB45 status is an important
guide but sometimes a more definite conclusion is achieved with
MIB1. Naeuc cells should show no positivity with this stain,
but melanoma would be expected to show at least some positive
nuclei.

The interpretation of MIB1 can be difficult in lymph nodes
because of the high proportion of positivity in surrounding
lymphocytes. P16 can be used in a similar way being usually
positive in naeuc cells and lost in melanoma.

We have identified naeuc cells in 279 SLN patients. Sixty-
two (22.2%) of these were associated with melanoma metas-
tases but the majority (217) were not.

WHICH PATIENTS SHOULD BE OFFERED SLNB

The criteria of the primary melanoma that are used to justify
performing SLNB are not standardised but most commonly a
minimum thickness of 1 mm has been used. Others have
suggested that there is no benefit in performing SLNB on
patients with melanomas thicker than 4 mm since these are
already known to have a bad prognosis. However, we would
argue that a large proportion (40%) of the thick melanomas still
have long-term survival and therefore the SLN can be used to
attempt to identify that particular group. We originally
considered that any patients with a melanoma in vertical
growth phase should be offered SLNB and we did identify
several patients with melanomas less than 1 mm down to
0.6 mm thickness that had metastasised. Nevertheless, the
number of such cases was a small proportion of the total and
therefore began to restrict offering SLNB to patients with
melanoma thicker than 1 mm. Gimoto et al20 have suggested
that thin melanomas (<1 mm) can be graded in risk according
to their mitotic counts and the gender of the patient. Males
with thin and invasive mitotically active melanomas are said to
have a 31% risk of metastasis and females a 13% risk. Therefore
we have begun to offer SLNB to patients with thin melanomas
dermal mitoses that by definition are in vertical growth
phase.

Regression has also long been considered as an important
feature of melanomas, with implications of an adverse effect on
prognosis by some. This effect is not accepted universally and
there are roughly equal numbers of studies who regard
regression as having an unfavourable effect on survival as those
who consider it to have no or even a favourable effect.21
Nevertheless prognostic tables22 showed regression as a poor
prognostic factor and for that reason we did use it as a criterion
for offering SLNB.

Our own studies23 comparing melanoma patients with or
without regression in terms of SLN status, as a surrogate for
survival, showed as one might expect intuitively that regression
appeared to confer benefit to the patient, therefore we have
discontinued accepting regression as a criterion.

Morton et a5 have identified some prolongation of disease-
free survival with SLNB on melanomas with thickness between
1.2 and 4 mm but this does not imply that SLNB should only be
offered to patients with this range of thickness of melanoma
since the staging benefits also apply to those outside this group.

At this stage we think it appropriate to offer SLNB to all
patients with melanoma over 1.0 mm in thickness and to those
patients with thinner invasive melanomas in which mitoses are
identified in the dermal component unless there are other
clinical features that override this decision.
less of that in the SLN.

Reported a definition of SLN based on the ratio of radioactivity assessment of SLN, but has not yet concluded its study. It has histology and also proposes to evaluate the role of RT-PCR in improvement in disease-free survival compared with no SLNB.

The first multicentre SLN trial (MSLT-1) has made a preliminary report. In 1269 patients, this trial has shown that in that positive nodes conferred a 5-year survival rate of 72.3% in patients with negative SLN and RND only on clinical evidence of metastasis. The SLN status was confirmed as a potent prognostic factor in that positive nodes conferred a 5-year survival rate of 72.3% compared with the latter showing greater tendency to haematogenous metastases.

This is supported by the findings of Viros et al. in which patients under 55 years were much more likely to have melanomas with BRAF mutation than older patients. This supports the growing support for the idea that melanoma is not one diagnosis but a collection of melanocytic tumours with different behaviours.

A FUTURE ROLE FOR RT-PCR

The MSLT-2 proposals have been stimulated in part by the observations of further RT-PCR studies that indicate that RT-PCR positive, histologically negative SLN have a worse prognosis than those that are negative by both techniques. Our recent studies (unpublished) also suggest that nodal metastases detected by melanoma-specific markers such as MAGE-3 revealed by RT-PCR on paraffin-embedded tissue from SLN gives an added dimension to the prognosis beyond that which can be obtained with histology alone. However, the process is laborious, therefore potentially expensive, and only dissects out an additional group of poorer prognosis patients from those 70% or so who are negative by histology. Rather than perform this additional assessment on the whole 70% of SLN that are negative, there is a need for a way of focussing on those within that group who are more likely to be positive. This would make this procedure more likely to be acceptable. For example, perhaps RT-PCR would be predictably negative in SLN-negative patients who were thinner than say 1.2 mm and had no mitoses in the dermis, or were of a histological type with suspected better prognosis such as spindle cell melanomas, or had a diffuse and intense tumour-infiltrating lymphocyte response.

Conversely SLN-negative cases that are histologically negative, but have a high mitotic count, would be expected to be more likely to be positive with RT-PCR.

IMPROVEMENT OF PREDICTIVE ACCURACY OF HISTOLOGICAL ASSESSMENT OF SLN ACCORDING TO “TUMOUR BURDEN”

A straightforward record of presence or absence of metastases in SLN has great prognostic value, but several authors have considered whether specific features of the metastases or their distribution may give more precise prognostic information. Starz et al. described an index derived from the depth of the metastases from the capsule and the number of slices involved. This index enabled a prediction of the status of the rest of the lymph nodes in the same basin to be made with considerable accuracy. Cochran was able to provide increased accuracy of survival prediction by using a relative tumour area calculation, based on some computer-facilitated measurement and calculations.

Our group noted a correlation between the microanatomic distribution of the metastases in the SLN and the presence of additional metastases in the RND. Those patients in whom the metastases were entirely subcapsular (fig 2) were found not to have any metastases in the nodes of the subsequent RND. The subcapsular pattern was seen in approximately 30% of all positive SLN. More recently Van Akkooi et al. showed that metastases <0.1 mm in maximum dimension, irrespective of site, were not associated with further metastases or any evidence of tumour progression. Govindarajan et al. supported similar findings in noting that patients with metastases <0.2 mm maximum dimension did not have positivity in their RND. There have been no recurrences in this group although

### Table 1 Sequence of sectioning and staining for sentinel lymph node for melanoma

<table>
<thead>
<tr>
<th>Section</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Section 1 (first full section)</td>
<td>H&amp;E</td>
</tr>
<tr>
<td>Section 2</td>
<td>S100</td>
</tr>
<tr>
<td>Section 3</td>
<td>Spare</td>
</tr>
<tr>
<td>50 µm gap (+50 µm)</td>
<td></td>
</tr>
<tr>
<td>Section 4</td>
<td>H&amp;E</td>
</tr>
<tr>
<td>Section 5</td>
<td>S100</td>
</tr>
<tr>
<td>Section 6</td>
<td>Spare</td>
</tr>
<tr>
<td>Section 7</td>
<td>Spare</td>
</tr>
<tr>
<td>Section 8</td>
<td>Spare</td>
</tr>
<tr>
<td>Section 9</td>
<td>Spare</td>
</tr>
<tr>
<td>50 µm gap (+100 µm)</td>
<td></td>
</tr>
<tr>
<td>Section 10</td>
<td>H&amp;E</td>
</tr>
<tr>
<td>Section 11</td>
<td>S100</td>
</tr>
<tr>
<td>Section 12</td>
<td>Spare</td>
</tr>
<tr>
<td>50 µm gap (+150 µm)</td>
<td></td>
</tr>
<tr>
<td>Section 13</td>
<td>H&amp;E</td>
</tr>
<tr>
<td>Section 14</td>
<td>S100</td>
</tr>
<tr>
<td>Section 15</td>
<td>Spare</td>
</tr>
<tr>
<td>50 µm gap (+200 µm)</td>
<td></td>
</tr>
<tr>
<td>Section 16</td>
<td>H&amp;E</td>
</tr>
<tr>
<td>Section 17</td>
<td>S100</td>
</tr>
<tr>
<td>Section 18</td>
<td>Spare</td>
</tr>
<tr>
<td>50 µm gap (+250 µm)</td>
<td></td>
</tr>
<tr>
<td>Section 19</td>
<td>H&amp;E</td>
</tr>
<tr>
<td>Section 20</td>
<td>S100</td>
</tr>
</tbody>
</table>

In large or round lymph nodes, the 50 µm gap may be increased up to a maximum of 100 µm.

MULTICENTRE SLN TRIALS

The first multicentre SLN trial (MSLT-1) has made a preliminary report. In 1269 patients, this trial has shown that SLNB with immediate RND for positive cases had a 4.8% improvement in disease-free survival compared with no SLNB and RND only on clinical evidence of metastasis.

The SLN status was confirmed as a potent prognostic factor in that positive nodes conferred a 5-year survival rate of 72.3% on the patients compared with 90.2% in patients with negative SLN. No overall survival benefit was noted at 5-year follow-up. This does not exclude the possibility of survival advantage being demonstrated after longer follow-up since metastases from thinner melanomas tend to occur later if at all.

The second multicentre SLN trial (MSLT-2) proposes to evaluate whether it is necessary to proceed to RND in all patients with positive SLN irrespective of the tumour burden, and also to further examine the role of RT-PCR positivity in histologically negative SLN. Some cases that are histologically negative but positive on RT-PCR will still enter the trial.

The Sunbelt melanoma trial, which is another multicentre study, emphasises the prognostic and staging value of SLNB histology and also proposes to evaluate the role of RT-PCR in assessment of SLN, but has not yet concluded its study. It has reported a definition of SLN based on the ratio of radioactivity in a node to that in the background. The latter should be 10% or less of that in the SLN.

The Sunbelt trial has not identified factors in the SLN metastases that enable prediction of metastases elsewhere and therefore they advocate completion lymphadenectomy for every patient with a positive SLN. They have noted a lower rate of metastases to SLN in older patients despite the shorter survival in the same group, suggesting that the biology of melanomas of younger patients is often different from that of older patients,
the follow-up period was short. These findings require further study as the number of such cases that were not subcapsular was very small. In addition Scherl et al have noted that metastases <0.2 mm in maximum dimension have a significantly higher risk of melanoma-specific death than SLN-negative patients thereby questioning the assumption that small metastases have limited significance.

These assessments of tumour burden all have merits, but whether one is more accurate or appropriate than another is not finally decided. All of them depend on careful examination of all available sections since metastases are not necessarily present in all. The Starz technique is perhaps most simple to assess being a measure from the capsule to the deepest metastasis. However one could ask from which part of the capsule does one measure. Logically it should be from the afferent aspect, but this is not always obvious.

Van Akkooi et al recommends the maximum dimensions of the largest deposit; this sounds straightforward but it needs to be understood that they mean the largest cohesive groups of cells, even though that may be only one of many, each of them showing only slight separation from each other.

The location of the metastases in our hands gives more reliable information, very easily assessed, in that subcapsular metastases are only very rarely associated with metastases in the rest of the nodes in the same basin. Even so, the definition of subcapsular site needs to be considered carefully. Subcapsular sinuses are not clearly visible and metastases in that zone are not usually identifiable as in a lumen. Their subcapsular zone location is important, with the configuration of the deposit being reasonably smooth, that is with no irregular projections on the parenchymal aspect.

On the basis of these studies it seems reasonable to presume that prognosis based on SLN can be refined, and that low volume, small or subcapsular metastases may not need to be followed by RND, although the criteria accepted may require further refinement. Whether these small or subcapsular metastases are precursors to larger tumours or represent a different character of metastases with more indolent growth properties remains to be established. It seems likely to us that they represent a mixture of early but potentially aggressive metastases with some more indolent ones.

In the meantime the European Organization for Research and Treatment of Cancer (EORTC) has suggested a clinical trial of melanoma patients with SLN metastases confined to the subcapsular zone or less than 0.1 mm in maximum dimension irrespective of site. These will be followed by observation for 5 years in the first instance. If these metastases are not associated with further disease then there would be some validation of a more selective approach to RND. It would also put more pressure on pathologists to assess the SLNB in greater detail. At the moment these assessments are performed only as part of studies or trials, but virtually all patients having SLNB are in that category since the procedure is to a large extent still being evaluated.

**SUMMARY: PART 1**

**Proposals for SLN assessment**

On the basis of our work and other published work we suggest that SLN for melanoma should be bivalved according to Cochran’s method. The resulting paraffin-embedded blocks should be sectioned in a stepwise manner.

We currently use 50 µm steps producing six pairs of sections to an approximate total depth of 0.3–0.4 mm. There is an argument to make the steps wider or less numerous, but bearing in mind the small size of many metastases and our lack of certainty on the critical dimension of the metastases we feel this change in protocol needs to be done in a systematic way. Van Akkooi et al suggest metastases <0.1 mm diameter can be ignored. The EORTC observation study, in part, is intended to validate that observation and therefore we will continue with the existing EORTC protocol of six pairs of sections at 50 µm intervals at least until that study reports.

We have strongly recommended the need for immunohistochemistry in the assessment partly because the detection rate is then higher and partly because the recognition of metastases is much facilitated, making the pathologist’s task less onerous. Whether S100 or Melan A is used is a matter of personal choice. It is wise to retain some unstained sections at each level for problematic cases.

The features that should be recorded are not only the presence of metastases but their site and size.

A metastasis in a subcapsular site but with a markedly irregular aspect towards the parenchyma or single cells breaking away from the main metastasis should not be regarded as being entirely subcapsular in site.

Other measurements on which further refinements of management may be based are the depth of the metastasis from the capsule to its deepest point, and the maximum dimension of the largest deposit. Van Akkooi et al have suggested that this last dimension should be applied only to cohesive groups of cells rather than looser aggregates. Groups of 10 cells or less are already regarded by that group as negative. Others are taking a more cautious line and would prefer to await the results of more studies on this point. Since, at least in the UK, the SLNB procedure is not regarded as standard, and in all countries is being carefully evaluated, it is not suggested that the pathological assessments should simply be loaded onto pathology departments without careful consideration of the labour or cost implications. Furthermore, it is important that committed pathologists are involved in the reporting of SLN to ensure the reproducibility of the detailed assessments currently being undertaken in multicentre trials.

---

*Figure 2* Screening of sentinel lymph node stained with S100 facilitates identification of metastatic melanoma. Distinction from dendritic cells, seen lower left, is made on the basis of cytology, with the dendritic cells having a poorly defined outline and smaller nuclei. The H&E-stained adjacent section enables confirmation of the cytological features and the site of the metastasis—in this case subcapsular.
My approach

We accept that SLNB for melanoma is in a phase of assessment and therefore we believe that the criteria we have set out and any new criteria need to be evaluated critically before discarding or adopting them formally as recommendations for general application.

SUMMARY: PART 2
Provable further developments

A lower threshold of the primary melanoma for entry to SLNB could be considered as well as greater reliance on mitotic activity, particularly in males, and perhaps in due course on genetic profile. Since currently at least 70% of patients having SLNB have negative results, a greater focus on those who are more likely to be positive is predicted. This may be achieved by changes to the criteria of the primary melanoma used to justify performing SLNB.

It is also possible that RND will be offered to only those patients with metastases involving a parenchymal site or above a certain size.

There is some curiosity that some patients (30%) with histologically negative SLNB nevertheless still develop recurrent disease and have a poor prognosis. Molecular studies may play a role at this point. Attempts will be made to predict who these patients are, using more specific markers.

If RT-PCR is adequately validated it is possible that the protocol for sectioning and staining could become less extensive.

COMPETING INTERESTS

There is some curiosity that some patients (30%) with metastases involving a parenchymal site or above a certain size.

Tumour infiltrating lymphocytes (TIL) in the primary melanoma have prognostic significance in some studies. TIL in metastases may have a similar significance.

Irrespective of the controversy that SLNB seems to provoke it has stimulated much interesting analysis of the biological processes involved in metastasis, some of which may result in more beneficial therapy for the patients than the SLNB itself, and therefore it is likely to remain an important part of the management of melanoma patients for many years. It provides a major opportunity for pathologists to play a pivotal role in melanoma research and management.

COMPETING INTERESTS: None declared.

REFERENCES

18. van Akkooi ACJ, de Wit JHW, Hoeverh C, et al. Clinical relevance of melanoma micrometastases (&lt;0.1 mm) in sentinel nodes: are these nodes to be considered negative? Ann Oncol 2006;17:578–85.